Naltrexone
نویسندگان
چکیده
منابع مشابه
Naltrexone/Bupropion
In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg. The drug has been tested in four randomized, double-blind, placebo-controlled, phase III trials and the co-primary endpoints were met in...
متن کاملNaltrexone/Bupropion ER (Contrave)
164 P&T® • March 2016 • Vol. 41 No. 3 INTRODUCTION Obesity is becoming an increasingly serious and costly health problem in the United States, with more than one-third of adults (34.9%) and 17% of children suffering from this condition.1 Obesity is defi ned as having a body mass index (BMI) greater than 30, while being overweight is defi ned as having a BMI between 25 and 29.9.2 Besides being a...
متن کاملNaltrexone: Different Protocols
Eight double-blind placebo-controlled clinical trials in five countries have demonstrated the safety and efficacy of naltrexone as an adjunct in alcoholism treatment. The efficacy depends, however, on how naltrexone is used. Three of the trials tested naltrexone two ways: 1) with supportive therapy, i.e., support of complete abstinence, 2) with therapy tacitly accepting that relapses may occur ...
متن کاملNaltrexone decreases self-injurious behavior.
The effect of naltrexone (0.5, 1.0, 1.5, and 2.0 mg/kg) on the frequency of self-injurious behavior (SIB) was investigated in three male adolescents. The frequency of total SIB was reduced significantly in all three subjects; dose-dependent decreases (at 0.5, 1.0, and 1.5 mg/kg) in SIB frequency were observed in the two mentally retarded subjects. These data suggest a role for opioid peptides i...
متن کاملNaltrexone implants In the first randomised controlled trial of naltrexone implants,
In the first randomised controlled trial of naltrexone implants, Kunøe et al identify two inclusion criteria in their methodology: being an in-patient and being 18 years or above. Exclusion criteria are given as psychosis, pregnancy and serious hepatic disease. Of 667 possible participants, 480 are excluded. In the results, the term ‘ineligibility’ is used to describe not completing treatment, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-95222-4